200 research outputs found
ν체λμ κ²μ¬μ λ²μμ§λ°μμ λ³΄μΈ νμμμ μ΅μλ°μκ°λ μ νꡬμ μ μ μν ν¨κ³Ό
Background:In patients who had serum autoantibody that reacted with all screening red blood cells (panagglutination), waiting for compatible blood is likely to delay a needed transfusion. In some cases of severely diminished hemoglobin counts, the least incompatible blood may be transfused. However, the least incompatible transfusion therapy is challenged by the presence of unexpected antibody in patient's serum, which may cause a transfusion reaction. The aim of this study was to evaluate the effect of the least incompatible transfusion on clinical outcomes in patients with panagglutination.
Methods:We conducted a retrospective study of 49 patients with panagglutination on an unexpected antibody screening test between January 2006 and July 2010. In 36 patients having the least incompatible blood transfusion, changes in hemoglobin and lactate dehydrogenase (LD) values before and after transfusion were analyzed. One year mortality after initial need for transfusion was documented.
Results:In all 36 patients who underwent transfusion, hemoglobin values showed an increase of 1.2 (0.0βΌ3.0) g/dL per unit without occurrence of acute transfusion reactions indicated by an increase in the LD level. The least incompatible transfusion did not show an association with increased all-cause mortality.
Conclusion:As an alternative to the time consuming process of alloantibody detection, patients with severe anemia can be effectively transfused with "least incompatible units" in an emergency clinical setting without experiencing acute transfusion reactions.ope
Serious Adverse Transfusion Reactions Reported in the National Recipient-Triggered Trace Back System in Korea (2006-2014).
BACKGROUND: Adverse transfusion reactions (ATRs) are clinically relevant to patients with significant morbidity and mortality. This study aimed to review the cases of ATR reported in the recipient-triggered trace back system for a recent nine-year period in Korea.
METHODS: Nine-year data obtained from 2006 to 2014 by the trace back system at the Division of Human Blood Safety Surveillance of the Korean Centers for Disease Control (KCDC) were reviewed. The suspected cases were assessed according to six categories: (i) related to, (ii) probably related to, (iii) probably not related to, (iv) not related to transfusion, (v) unable to investigate, and (vi) under investigation.
RESULTS: Since 2006, 199 suspected serious ATRs were reported in hospitals and medical institutions in Korea, and these ATRs were reassessed by the division of Human Blood Safety Surveillance of the KCDC. Among the reported 193 cases as transfusion related infections, hepatitis C virus (HCV) infection (135, 67.8%) was reported most frequently, followed by hepatitis B virus (HBV) infection (27, 13.6%), HIV infection (13, 6.5%), syphilis (9, 4.5%), malarial infection (4, 2.0%), other bacterial infections (3, 1.5%), HTLV infection (1, 0.5%), and scrub typhus infection (1, 0.5%), respectively. Of the 199 cases, 13 (6.5%) cases were confirmed as transfusion-related (3 HCV infections, 3 malarial infections, 1 HBV infection, 2 Staphylococcus aureus sepsis, 3 transfusion-related acute lung injuries, and 1 hemolytic transfusion reaction).
CONCLUSIONS: This is the first nationwide data regarding serious ATRs in Korea and could contribute to the implementation of an effective hemovigilance system.ope
Report on the Project for Establishment of the Standardized Korean Laboratory Terminology Database, 2015
The National Health Information Standards Committee was established in 2004 in Korea. The practical subcommittee for laboratory test terminology was placed in charge of standardizing laboratory medicine terminology in Korean. We aimed to establish a standardized Korean laboratory terminology database, Korea-Logical Observation Identifier Names and Codes (K-LOINC) based on former products sponsored by this committee. The primary product was revised based on the opinions of specialists. Next, we mapped the electronic data interchange (EDI) codes that were revised in 2014, to the corresponding K-LOINC. We established a database of synonyms, including the laboratory codes of three reference laboratories and four tertiary hospitals in Korea. Furthermore, we supplemented the clinical microbiology section of K-LOINC using an alternative mapping strategy. We investigated other systems that utilize laboratory codes in order to investigate the compatibility of K-LOINC with statistical standards for a number of tests. A total of 48,990 laboratory codes were adopted (21,539 new and 16,330 revised). All of the LOINC synonyms were translated into Korean, and 39,347 Korean synonyms were added. Moreover, 21,773 synonyms were added from reference laboratories and tertiary hospitals. Alternative strategies were established for mapping within the microbiology domain. When we applied these to a smaller hospital, the mapping rate was successfully increased. Finally, we confirmed K-LOINC compatibility with other statistical standards, including a newly proposed EDI code system. This project successfully established an up-to-date standardized Korean laboratory terminology database, as well as an updated EDI mapping to facilitate the introduction of standard terminology into institutions.ope
μ§λ°°Β·μ’ μνμ¬μμμ μ£Όμ£Ό μ΄μ΅ 보νΈμ κ΄ν λΉκ΅λ²μ μ°κ΅¬
νμλ
Όλ¬Έ (λ°μ¬)-- μμΈλνκ΅ λνμ λ²κ³Όλν λ²νκ³Ό, 2017. 8. μ‘μ₯λ ¬.μ¬λ¬ νμ¬κ° κΈ°μ
μ§λ¨μ μ΄λ£¨μ΄ μ΄μλκ³ μ΄λ¬ν κΈ°μ
μ§λ¨μ΄ νλμ κ²½μ μ νλ λ¨μλ‘ μΈμλκ³ μλ κ²μ΄ μΈκ³μ μΆμΈμ΄κ³ , μ°λ¦¬λλΌλ μμΈλ μλλ€. κΈ°μ
μ§λ¨ μ°¨μμ μμ¬κ²°μ μ΄ μ΄λ£¨μ΄μ§λ©΄, κ·Έ κ³Όμ μμ κΈ°μ
μ§λ¨ νΉμ μ λ¬Έμ κ° λ°μνκ³ , κ·Έμ λ°λΌ 보νΈλμ΄μΌ νλ κΈ°μ
μ§λ¨ λ΄ μ΄ν΄κ΄κ³μλ€μ μ΄μ΅λ λ¬λΌμ§λ€. λ°λΌμ κ·Έλ¬ν μ΄ν΄κ΄κ³λ₯Ό μ μ νκ² μ‘°μ νλ κ²μ΄ νμ¬λ²μ μ€μν κ³Όμ κ° λλ€.
κ·Έλ¬λ νκ΅ μλ²μ λ
립ν λ²μΈκ²©μ κ°μ§ κ°λ³ νμ¬λ₯Ό λ¨μλ‘ λ²λ₯ κ΄κ³λ₯Ό μ νκ³ μκ³ , λͺλͺ μ‘°λ¬Έμ μ μΈνκ³ λ κΈ°μ
μ§λ¨μ κ΄ν κ·μ μ λκ³ μμ§ μλ€. νκ΅ λ²μλ κΈ°μ
μ§λ¨ λ¨μμμ μ΄λ£¨μ΄μ§ μμ¬κ²°μ μ΄λΌλ κ°λ³ νμ¬λ₯Ό λ¨μλ‘ νμ¬ λ²μ νλ¨μ νκ³ μλ μ€μ μ΄λ€. μ΄λ¬ν νμ€μμλ κΈ°μ
μ§λ¨ λ΄μμ λ°μνλ λ¬Έμ λ€μ λν ν©λ¦¬μ μΈ λμ²λ₯Ό νκΈ° νλ€κ³ , κ²°κ΅ μ΄ν΄κ΄κ³μλ€μ μ΄μ΅μ μ λλ‘ λ³΄νΈνκΈ° μ΄λ ΅κ² λλ€.
λ³Έ λ
Όλ¬Έμμλ κΈ°μ
μ§λ¨μ λ°λΌλ³΄λ νν μλ²κ³Ό λ²μμ νλλ 극볡λμ΄μΌ ν¨μ μ£Όμ₯νλ€. κΈ°μ
μ§λ¨μ λν μ΄λ
νμΌλ‘μ νλμ μ’
μνμ¬μ μ΄ νμ¬μ κ²½μμ μ§λ°°νκ³ μλ νλμ μ§λ°°νμ¬λ₯Ό μ°κ΅¬μ λμμΌλ‘ νμ¬, μ§λ°°Β·μ’
μκ΄κ³μ μλ νμ¬λ€μ λ²λ₯ κ΄κ³λ κ°λ³ νμ¬μμμ λ²λ₯ κ΄κ³μλ λ€λ₯΄λ€λ μ μ κ³ μ°°νλ€. μ§λ°°νμ¬ λ° μ’
μνμ¬μ μ£Όμ£Ό μ΄μ΅ 보νΈμ κ΄μ μμ, μ§λ°°Β·μ’
μνμ¬μ μ΄μκ³Όμ μμ λ°μν μ μλ νΉμ μ μμ λ€μ΄ 무μμΈμ§ μ°Ύμλ΄μ΄ μ΄λ₯Ό λΆμνκ³ , λΉκ΅λ²μ κ³ μ°°μ ν΅ν ν΄κ²°μ±
μ κ°κ΅¬νλ€. μ΄ κ³Όμ μμ κΈ°μ‘΄ νμ¬λ²μ λν μλ‘μ΄ ν΄μλ‘ λλ μ
λ²λ‘ μ μ μνλ€.
λ¬Έμ μν©μ ν¬κ² μ’
μνμ¬ μ΄μ¬μ μν μ’
μνμ¬ κ°μΉ κ°μ νμκ° 1) μ§λ°°νμ¬λ κ·Έλ£Ήμ΄μ΅μ μΆκ΅¬μ 무κ΄νκ² μ΄λ£¨μ΄μ§ κ²½μ°μ 2) μ§λ°°νμ¬λ κ·Έλ£Ήμ μ΄μ΅μ μΆκ΅¬νλ κ³Όμ μμ μ΄λ£¨μ΄μ§ κ²½μ°λ‘ λλμ΄ μ΄ν΄λ³Έλ€.
1)μ μν©μ μ’
μνμ¬ κ°μΉ κ°μκ° μ§λ°°νμ¬μ κ°μΉ κ°μλ‘ μ΄μ΄μ§ μ μμΌλ―λ‘ μ§λ°°νμ¬ μ£Όμ£Όλ€μ μ΄μ΅μ μν₯μ λ―ΈμΉλ νμκ° μ’
μνμ¬ λ¨κ³μμλ λ°μν μ μμμ μλ―Ένλ€. λ°λΌμ μ’
μνμ¬μ κ°μΉ κ°μ λ°©μ§λ ν볡 λ±μ ν΅ν΄ μ§λ°°νμ¬ μ£Όμ£Όλ₯Ό 보νΈν νμκ° μμμ νΌλ ₯νλ€. κ·Έ λ°©μμ μ§λ°°νμ¬κ° μ’
μνμ¬μ λν΄ κ°μ§λ μΌλ° μ£Όμ£Όλ‘μ λΏ μλλΌ μ§λ°°μ£Όμ£Όλ‘μ κ°μ§λ κΆλ¦¬λ₯Ό νμ¬ν¨μΌλ‘μ¨ μ§λ°°νμ¬ λ¨κ³μμ λ²μΈκ²©μ΄ λ€λ₯Έ μ’
μνμ¬μ κ΄λ¦¬μ μ΄μμ λνμ¬ κ΄μ¬νλ ꡬ쑰λ₯Ό λ§λλ κ²μ΄λ€. ꡬ체μ μΌλ‘λ β
°) μ§λ°°νμ¬ μ΄μ¬μκ² μ’
μνμ¬μ κ°μ
νμ¬ κ΄λ¦¬κ°λ
ν μ무λ₯Ό λΆλ΄νλλ‘ νλ λ°©λ²κ³Ό β
±) μ§λ°°νμ¬ μ£Όμ£Όμκ² μ§μ μ’
μνμ¬μ κ΄μ¬ν μ μλ κΆνμ λΆμ¬νλ λ°©λ²μΌλ‘ λνλλ€.
β
°) μ§λ°°νμ¬μ μ
무μ§νμλ‘μ μ§λ°°νμ¬ μ΄μ¬λ μ§λ°°νμ¬κ° 보μ νλ μμ°μ νμ©νμ¬ μ§λ°°νμ¬μ κ°μΉλ₯Ό κ·Ήλνν μλ¬΄κ° μλλ°, μ’
μνμ¬μ μ£Όμλ μ§λ°°νμ¬μ μμ°μ΄λ―λ‘, μ§λ°°νμ¬ μ΄μ¬λ μ’
μνμ¬ μ£Όμμ νμ©νμ¬ μ§λ°°νμ¬μ κ°μΉλ₯Ό κ·Ήλνν μ무λ₯Ό μ§λ°°νμ¬ μ£Όμ£Όμ λν μ κ΄μ£Όμμ무λ‘μ λΆλ΄νλ€. μ΄λ μ§λ°°νμ¬ μ΄μ¬λ μ’
μνμ¬μ μ£Όμμ λΆμ°©λ μ§λ°°νμ¬μ λ²λ₯ μ μ£Όμ£ΌκΆ λΏ μλλΌ μ§λ°°νμ¬κ° μ§λ°°μ£Όμ£Όλ‘μ κ°μ§λ μ¬μ€μ μ§λ°°μ μν₯λ ₯ λ± λͺ¨λ κ²μ νμ©νμ¬ μ§λ°°νμ¬μ κ°μΉ κ·Ήλνλ₯Ό μνμ¬ νμνμ¬μΌν μλ¬΄κ° μλ€κ³ ν¨μΌλ‘μ¨ μ§λ°°νμ¬ μ΄μ¬μ μ§λ°°νμ¬μ λν μ’
μνμ¬ κ΄λ¦¬κ°λ
μ무λ₯Ό λμΆνλ€.
μμΈλ¬ μ§λ°°νμ¬ μ΄μ¬μ κ΄λ¦¬κ°λ
μ무 μ΄νμλ¨μΌλ‘μ μ§λ°°νμ¬ μ΄μ¬μκ² μ’
μνμ¬μ λν μ§μκΆ, μ’
μνμ¬μ κ΄ν μ 보μμ§κΆμ μΈμ ν νμκ° μμμ μ£Όμ₯νλ€. μ΄λ¬ν κΆνμ μ§λ°°νμ¬κ° μ§λ°°μ£Όμ£Όλ‘μ μ’
μνμ¬μ λν΄ κ°μ§λ κΆλ¦¬λ‘λΆν° λμ€κ³ , μ’
μνμ¬ μ΄μ¬λ₯Ό ꡬμνκΈ° μν΄μλ λ²μ μΈ κ·Όκ±°κ° νμνλ€λ κ²μ λͺ
νν νλ€. λν μ§λ°°νμ¬ μ΄μ¬μ κ΄λ¦¬κ°λ
μ무 μ΄ν μ¬λΆλ₯Ό κ°μΒ·κ°λ
νκΈ° μν μλ¨μΌλ‘μ μλ² μ 412μ‘°μ5μ κ·μ λ μ§λ°°νμ¬ κ°μ¬μ μ’
μνμ¬μ λν μ‘°μ¬κΆμ νμ©λ°©μλ ν¨κ» κ²ν νλ€.
β
±) λ²μΈκ²© λ
립μ μμΉμ λ°λ₯΄λ©΄, μ’
μνμ¬μμ μ’
μνμ¬ κ°μΉ κ°μ νμκ° μ΄λ£¨μ΄μ§λλΌλ μ§λ°°νμ¬ μ£Όμ£Όλ μ’
μνμ¬μ μ£Όμ£Όκ° μλλ―λ‘ μ’
μνμ¬μ κ΄ν μμ¬κ²°μ μ κ΄μ¬νκ±°λ μν΄ν볡μ μν μ‘°μΉλ₯Ό μ·¨ν μ μλ€. κ·Έλ¬λ μ§λ°°νμ¬ μ΄μ¬λ€μ΄ μ’
μνμ¬ κ΄λ¦¬κ°λ
μ무μ μ΄νμ κ²μ리 νκ±°λ μ§λ°°νμ¬ μ£Όμ£Όμ μ΄μ΅κ³Όλ 무κ΄νκ² νμνλ κ²½μ°μλ μ§λ°°νμ¬ μ£Όμ£Όμ μ΄μ΅ 보νΈλ₯Ό μν΄ μ§λ°°νμ¬ μ£Όμ£Όμκ² μ§μ μ’
μνμ¬μ κ΄μ¬ν μ μλ κΆνμ λΆμ¬νμ¬μΌ ν¨μ μ£Όμ₯νλ€. μ§λ°°νμ¬ μ£Όμ£Όμ κΆνμ λ²μΈκ²©μ΄ λ€λ₯Έ μ’
μνμ¬μ λνμ¬ νλμν¬ μ μλ κ²μ μ’
μνμ¬μ νκΈνλ¦μ λν μ€μ§μ μΈ μ΄ν΄κ΄κ³λ₯Ό κ°μ§λ μ§λ°°νμ¬ μ£Όμ£Όκ° μ’
μνμ¬μ μ΄μ΅μ κ·Ήλνν μΈμΌν°λΈλ₯Ό κ°μ§κ³ μμΌλ―λ‘ μ’
μνμ¬μ κ΄ν μ
무μ§νμ μ°Έμ¬νκ³ κ°λ
ν μ μλ κΆνμ κ°μ§λ€λ λ
Όλ¦¬μ΄λ€.
μ§λ°°νμ¬κ° μ’
μνμ¬μ λν΄ κ°μ§λ κΆλ¦¬ μ€ μ’
μνμ¬μ μ€μν μ¬νμ κ΄ν μμ¬κ²°μ κΆ, λνμμ‘μ κΈ°κΆ, νκ³μ₯λΆμ΄λμ²κ΅¬κΆμ΄ μ§λ°°νμ¬ μ£Όμ£Όμκ² μ§μ μΈμ λμ΄μΌ ν¨μ μ£Όμ₯νκ³ , μ΄λ₯Ό μν μ
λ²λ°©μμ μ μνλ€.
2)μ μν©μ μ’
μνμ¬ μ΄μ¬κ° μ§λ°°νμ¬ μ΄μ¬μ μ§μμ λ°λΌ μ§λ°°νμ¬ λλ κ·Έλ£Ή μ 체μ μ΄μ΅μ μν΄ μ’
μνμ¬μ λΆμ΄μ΅ν νμλ₯Ό ν κ²½μ°μ κ°μ΄ μ§λ°°νμ¬λ κ·Έλ£Ήμ μ΄μ΅μ μΆκ΅¬νλ κ³Όμ μμ μ’
μνμ¬ μμμ£Όμ£Όμ μ΄μ΅μ΄ μΉ¨ν΄λλ μν©μ μλ―Ένλ€. λ°λΌμ μ΄ κ²½μ° μ’
μνμ¬ μμμ£Όμ£Ό μ΄μ΅ 보νΈμ κ΄μ μμ μ’
μνμ¬ μ΄μ¬, μ§λ°°νμ¬ μ΄μ¬ λ° μ§λ°°νμ¬μ μ’
μνμ¬μ λν μ무μ μ±
μμ κ³ μ°°νλ€. μ’
μνμ¬ μ΄μ¬λ μ’
μνμ¬μ μ΄μ΅λ§μ μΆκ΅¬ν΄μΌ ν¨μλ κ·Έλ£Ήμ΄μ΅μΆκ΅¬νμλ₯Ό ν κ²½μ° μ’
μνμ¬μ λν μ κ΄μ£Όμμ무·좩μ€μ무 μλ°μΌλ‘ μν΄λ°°μμ±
μμ λΆλ΄νμ¬μΌ ν¨μ νμΈνλ€. μ§λ°°νμ¬ μ΄μ¬ λ° μ§λ°°νμ¬λ μ’
μνμ¬λ μ’
μνμ¬ μμμ£Όμ£Όμ λνμ¬ μ무λ₯Ό λΆλ΄νμ§ μλλΌλ μ’
μνμ¬ μ΄μ¬μ μ무 μλ°μ λν κ΅μ¬Β·λ°©μ‘°μ μ±
μμ μΈμ λλ€. μ΄μ²λΌ μ’
μνμ¬ μμμ£Όμ£Όμ λν μ±
μμ 주체λ₯Ό λ²μΈκ²©μ΄ λ€λ₯Έ μ§λ°°νμ¬λ μ§λ°°νμ¬ μ΄μ¬λ‘ νμ₯μν¬ μ μλ κ·Όκ±°λ₯Ό λΉκ΅λ²μ κ²ν λ₯Ό ν΅ν΄ κ³ μ°°νκ³ , μλ² 401μ‘°μ2 μ
무μ§νμ§μμ λ±μ μ±
μ κ·μ μ΄ μ΄λ¬ν κΈ°λ₯μ μννμ¬ μ§λ°°μ λ°λ₯Έ μ±
μμ λΆκ³Όνκ³ μμμ νμΈν ν, μ΄ κ·μ μ μ κ·Ήμ μΈ νμ©μ μν κ°μ λ°©μμ μ μνλ€.
ννΈ, μ’
μνμ¬μ μν΄κ° λλλΌλ μ₯κΈ°μ μΈ κ΄μ μμ λ΄€μ λλ μ§λ°°νμ¬ λλ κ·Έλ£Ή μ 체μ μ΄μ΅μ μΆκ΅¬νλ κ²μ΄ ν¨μ¨μ μΈ κ²½μ°κ° μλ€. μ΄λ¬ν κ²½μ°μ ν΄λΉνλ κ±°λμ μ νλ€μ λΆμνκ³ , μ§λ°°νμ¬μ μ’
μνμ¬κ° κ·Έ μ νμ ν΄λΉνλ κ±°λλ₯Ό νλ κ²½μ°μλ κ·Έλ£Ήμ μ€μ²΄λ₯Ό μΈμ νμ¬ μ§λ°°νμ¬ μ΄μ¬κ° μ’
μνμ¬ μ΄μ¬μ λνμ¬ κ·Έλ£Ή μ 체μ μ΄μ΅μ μν λΆμ΄μ΅ν μ§μλ₯Ό ν μ μμμ μ£Όμ₯νλ€. λ²μ νμμ ꡬμ λ°μ§ μκ³ κ²½μ μ μ€μ§μ κ³ λ €ν κ·Έλ£Ήμ΄μ΅ κ°λ
μ μΈμ νμλ κ²μΌλ‘ μ΅κ·Ό μ λ½μ λ§μ λλΌλ€μ΄ νλ‘ λλ μ
λ²μ ν΅ν΄ μ΄λ₯Ό μΈμ νκ³ μκΈ°λ νλ€. λ€λ§, κ·Έλ¬ν κ±°λ μ νμ μνκΈ°λ§ νλ©΄ μ’
μνμ¬ λ° μ§λ°°νμ¬ μ΄μ¬μ κ·Έλ£Ήμ΄μ΅μΆκ΅¬νμμ λν μ±
μμ΄ μ±λ¦½λμ§ μλ κ²μ΄ μλλΌ, μ§λ°°νμ¬μ μ’
μνμ¬κ° μμ μ§λ°°Β·μ’
μκ΄κ³μ μλ λ± μμμ£Όμ£Όλ₯Ό 보νΈν νμκ° μκ±°λ 보μ λ± μμμ£Όμ£Όλ₯Ό 보νΈν λ€λ₯Έ μ₯μΉκ° λ§λ ¨λμ΄ μλ κ²½μ°μ ννμ¬ κ·Έλ£Ήμ΄μ΅μ νλ³μ΄ μΈμ λμ΄μΌ ν¨μ κ°μ‘°νμλ€. κ·Έλ¦¬κ³ μ΄λ μ
λ²μ ν΅ν΄ κ·Έ μ건μ λͺ
νν ν κ²μ μ£Όμ₯νλ€. νΉν κ·Έλ£Ήμ΄μ΅μ νλ³μ΄ μ§λ°°μ£Όμ£Όμ μ¬μ΅ μΆκ΅¬λ₯Ό μν κ±°λμ μ μ©λλ μΌμ΄ μλλ‘, νλ³ μ건μ μΆ©μ‘±μ¬λΆμ λν΄μλ μ격ν μ¬μ¬κ° νμνλ€λ μΈκΈλ μμ§ μλλ€.μ 1μ₯ μλ‘ 1
μ 1μ μ°κ΅¬μ λ°°κ²½ λ° λͺ©μ 1
μ 2μ μ°κ΅¬ λ°©λ²κ³Ό μ°κ΅¬ λ²μ 3
μ 3μ μ°κ΅¬ λ΄μ© 4
μ 2μ₯ κΈ°μ΄μ κ³ μ°° 9
μ 1μ λ
Όμμ μ μ λ‘μ κΈ°μ
μ§λ¨ 9
β
. κΈ°μ
μ§λ¨μ μ μ 9
1. μ μ λ²μ κΈ°μ
μ§λ¨μ μ μ 9
2. κ°νμ κΈ°μ
μ§λ¨μ μ μ 9
β
‘. κΈ°μ
μ§λ¨ νμ± λ°°κ²½ 10
β
’. νκ΅ κΈ°μ
μ§λ¨μ νμ€ 13
1. 보νΈνλ κΈ°μ
μ§λ¨ λ¨μμ μ¬μ
μν λ° μ§μ£Όνμ¬μ μ¦κ° 13
2. λμ λ΄λΆκ±°λλΉμ€ 18
3. νμ¬μ±
μμ μν ν΄κ²° 21
μ 2μ μ§λ°°νμ¬Β·μ’
μνμ¬μ μμ 23
β
. κ°κ΄ 23
β
‘. μ§λ°°νμ¬Β·μ’
μνμ¬μ μ μ 23
1. μ§λ°°Β·μ’
μκ΄κ³μ κΈ°μ€ 23
2. λΉκ΅λ²μ κ³ μ°° 24
3. νκ΅ 33
β
’. λ³Έ λ
Όλ¬Έμ λ
Όμ λμμΌλ‘μ μ§λ°°νμ¬Β·μ’
μνμ¬ 36
1. ννλ²μ μ§λ°°Β·μ’
μ κ°λ
μ μ©μ νκ³ 36
2. λ³Έ λ
Όλ¬Έμ μ μ 40
μ 3μ κ°κ΅μ μ§λ°°Β·μ’
μνμ¬λ²μ 41
β
. μ 41
β
‘. μ§λ°°Β·μ’
μνμ¬μ κ΄ν μ
λ² λ°©μ 41
1. ν¬κ΄μ μ
λ² 41
2. λΆλΆμ μ
λ² 43
3. νλ‘λ²μ μν κ·μ¨ 44
4. λ³λμ κ·μ¨μ΄ μλ κ²½μ° 45
β
’. EUμ μ§λ°°Β·μ’
μνμ¬μ κ΄ν λ
Όμ 46
1. μ 9μ§μΉ¨μ 46
2. μ λ½ κ·Έλ£Ήλ²μ ν¬λΌ λ³΄κ³ μ 46
3. νμ¬λ² μ λ¬Έκ° κ·Έλ£Ή λ³΄κ³ μ 49
4. EU νμ¬λ² λ―Έλμ κ΄ν λ³΄κ³ μ 50
5. μ΄νμ μμ§μ 51
β
£. κ²ν 51
μ 3μ₯ μ§λ°°νμ¬ μ΄μ¬μ κ΄λ¦¬κ°λ
μ무μ κΆν 53
μ 1μ μ 53
β
. μ§λ°°νμ¬ μ£Όμ£Ό 보νΈμ νμμ± 54
β
‘. μ§λ°°νμ¬ μ£Όμ£Ό 보νΈμ λ°©μ 54
1. μ§λ°°νμ¬ μ΄μ¬μκ² μ§λ°°νμ¬μ κΆλ¦¬λ₯Ό νμ¬ν μ무 λΆμ¬ 54
2. μ§λ°°νμ¬ μ΄μ¬κ° νμ¬ν μ μλ μ§λ°°νμ¬μ κΆλ¦¬ 55
3. λ
Όμμ λ°©ν₯ 57
μ 2μ μ§λ°°νμ¬ μ΄μ¬μ κ΄λ¦¬κ°λ
μ무 58
β
. κ°κ΄ 58
β
‘. λΉκ΅λ²μ κ³ μ°° 60
1. λ―Έκ΅ 60
2. λ
μΌ 61
3. μΌλ³Έ 63
4. μμ¬μ 77
β
’. νκ΅ 79
1. νλ‘ 79
2. νμ€ 79
3. κ²ν 81
μ 3μ μ§λ°°νμ¬ μ΄μ¬μ μ’
μνμ¬ κ΄λ¦¬κ°λ
μλ¨ 84
β
. μ§λ°°νμ¬ μ΄μ¬μ μ’
μνμ¬μ λν μ§μκΆ 84
1. κ°κ΄ 84
2. λΉκ΅λ²μ κ³ μ°° 86
3. νκ΅ 91
β
‘. μ§λ°°νμ¬ μ΄μ¬μ μ’
μνμ¬μ κ΄ν μ 보μμ§κΆ 96
1. κ°κ΄ 96
2. λΉκ΅λ²μ κ³ μ°° 98
3. νκ΅ 105
β
’. μ§λ°°νμ¬ κ°μ¬μ μ’
μνμ¬μ λν μ‘°μ¬κΆ 107
1. κ°κ΄ 107
2. λΉκ΅λ²μ κ³ μ°° 109
3. νκ΅ 114
μ 4μ₯ μ§λ°°νμ¬ μ£Όμ£Όμ μ’
μνμ¬μ λν κΆν 118
μ 1μ μ 118
β
. μ§λ°°νμ¬ μ΄μ¬μ μ무λ₯Ό ν΅ν μ§λ°°νμ¬ μ£Όμ£Ό 보νΈμ νκ³ 118
β
‘. μ§λ°°νμ¬ μ£Όμ£Ό λ³΄νΈ λ°©μ 119
1. μ§λ°°νμ¬ μ£Όμ£Όμκ² μ§λ°°νμ¬μ κΆλ¦¬λ₯Ό νμ¬ν κΆν λΆμ¬ 119
2. μ§λ°°νμ¬ μ£Όμ£Όκ° νμ¬ν μ μλ μ§λ°°νμ¬μ κΆλ¦¬ 119
3. λ
Όμμ λ°©ν₯ 122
μ 2μ μ§λ°°νμ¬ μ£Όμ£Όμ μ’
μνμ¬μ κ΄ν μ¬νμ μκ²°κΆ νμ¬ 123
β
. κ°κ΄ 123
1. λ¬Έμ μ μμ¬ 123
2. νκ΅ μλ²κ³Ό νλ‘μ νλ 124
3. λ
Όμμ λ°©ν₯ 124
β
‘. λΉκ΅λ²μ κ³ μ°° 125
1. λ―Έκ΅ 125
2. λ
μΌ 131
3. μΌλ³Έ 137
4. μμ¬μ 137
β
’. νκ΅ 141
1. νμ€μ κ²½ν₯ 142
2. μΈμ μ¬λΆ 143
3. κ²ν 143
μ 3μ μ§λ°°νμ¬ μ£Όμ£Όμ μ’
μνμ¬ μ΄μ¬μ λν μ±
μμΆκΆ 150
β
. κ°κ΄ 150
1. λ¬Έμ μ μμ¬ 150
2. νκ΅ μλ²κ³Ό λ²μμ νλ 152
3. λ
Όμμ λ°©ν₯ 153
β
‘. λΉκ΅λ²μ κ²ν 154
1. λ―Έκ΅ 154
2. λ
μΌ 167
3. μΌλ³Έ 168
4. μμ¬μ 175
β
’. νκ΅ 176
1. νμ€μ κ²½ν₯ 176
2. μΈμ μ¬λΆ 178
3. κ²ν 180
μ 4μ μ§λ°°νμ¬ μ£Όμ£Όμ μ’
μνμ¬ μ 보μμ§κΆ 193
β
. κ°κ΄ 193
1. λ¬Έμ μ μμ¬ 193
2. νκ΅ μλ²κ³Ό νλ‘μ νλ 194
3. λ
Όμμ λ°©ν₯ 195
β
‘. λΉκ΅λ²μ κ³ μ°° 196
1. λ―Έκ΅ 196
2. λ
μΌ 201
3. μΌλ³Έ 202
4. μμ¬μ 206
β
’. νκ΅ 208
1. νμ€μ κ²½ν₯ 208
2. μΈμ μ¬λΆ 209
3. κ²ν 209
μ 5μ₯ μ’
μνμ¬ μμμ£Όμ£Ό λ³΄νΈ 219
μ 1μ μ 219
μ 2μ μ’
μνμ¬ μμμ£Όμ£Όμ λν μ무μ μ±
μ 221
β
. κ°κ΄ 221
β
‘. μ’
μνμ¬ μ΄μ¬μ μ무μ μ±
μ 221
1. μ’
μνμ¬ μ΄μ¬μ μ무 222
2. μ’
μνμ¬ μ΄μ¬μ μ±
μ 224
β
’. μ§λ°°νμ¬ μ΄μ¬ λ° μ§λ°°νμ¬μ μ무μ μ±
μ 225
1. μ§λ°°νμ¬ μ΄μ¬μ μ무 225
2. μ§λ°°νμ¬μ μ무 227
3. μ§λ°°νμ¬ μ΄μ¬ λ° μ§λ°°νμ¬μ μ±
μ 235
μ 3μ κ·Έλ£Ήμ΄μ΅ νλ³ 267
β
. κ°κ΄ 267
β
‘. κ·Έλ£Ήμ΄μ΅ νλ³μ μΈμ νκΈ° μν κ΄ν κΈ°μ΄μ κ³ μ°° 268
1. κ·Έλ£Ήμ΄μ΅(group interest)μ μμ 269
2. κΈ°μ
μ§λ¨μ μ€μ²΄μ κ΄ν μ κ·Ό λ°©μ 270
3. κ·Έλ£Ήμ΄μ΅ κ°λ
μΈμ μ λͺ©μ 276
4. κ·Έλ£Ήμ΄μ΅ νλ³μ μ μ©ν μ μλ κ±°λ μ ν 278
5. κ²ν 283
β
’. λΉκ΅λ²μ κ³ μ°° 284
1. μμμ£Όμ£Όκ° μ‘΄μ¬νλ κ²½μ° 284
2. μμμ£Όμ£Όκ° μ‘΄μ¬νμ§ μλ κ²½μ° 304
3. μμ¬μ 306
β
£. νκ΅ 309
1. ννλ²μ νλ 309
2. νμ€κ³Ό νλ‘μ νλ 310
μ 6μ₯ κ²°λ‘ 322
μ°Έκ³ λ¬Έν 326
Abstract 350Docto
Geometric structures modeled after smooth projective horospherical varieties of Picard number one
νμλ
Όλ¬Έ (λ°μ¬)-- μμΈλνκ΅ λνμ : μ리과νλΆ, 2016. 2. μμ ν¬.Geometric structures modeled after homogeneous manifolds are studied to
characterize homogeneous manifolds and to prove the deformation rigidity of
them. To generalize these characterizations and deformation rigidity results to
quasihomogeneous manifolds, we ο¬rst study horospherical varieties and geo
metric structures modeled after horospherical varieties. Using Cartan geom
etry, we prove that a geometric structure modeled after a smooth projective
horospherical variety of Picard number one is locally equivalent to the stan
dard geometric structure when the geometric structure is deο¬ned on a Fano
manifold of Picard number one.Chapter 1 Introduction 1
Chapter 2 Geometric structures on filtered manifolds 6
2.1 G0-structures on filtered manifolds 6
2.2 Prolongations 9
2.3 Cartan connections 11
2.4 Examples 15
Chapter 3 Smooth horospherical varieties of Picard number one 20
3.1 G-varieties 20
3.2 Classifications 22
3.3 Lie algebras of the automorphism groups 26
3.4 Gradations 29
3.5 Varieties of minimal rational tangents 43
Chapter 4 Existence of Cartan connections 50
4.1 Prolongations 50
4.2 Existence of Cartan connections 58
4.3 Geometric structures modeled after horospherical varieties 62
Bibliography 67
κ΅λ¬Έμ΄λ‘ 71Docto
Human adipose mesenchymal stem cells modulate inflammation and angiogenesis through exosomes
Stem cell-derived exosomes are efficient and safe therapeutic tools for transferring endogenous biological cargo or functional biomolecules for regenerative medicine. The regulation of inflammation and angiogenesis plays a pivotal role in wound healing and tissue regeneration. The purpose of this study was to investigate the anti-inflammatory and pro-angiogenic roles of human adipose mesenchymal stem cell-derived exosomes, focusing on the underlying mechanisms. Exosomes inhibited LPS-induced inflammation by activating ROCK1 and PTEN expression. Moreover, microRNAs (miR-132 and miR-146a) released from exosomes upregulated the expression of pro-angiogenic genes and promoted proliferation activity and tube formation in human umbilical vein endothelial cells. Exosomal effects were verified using ROCK1/PTEN inhibitors for anti-inflammation and miR-132/miR-146a inhibitors for pro-angiogenesis. Our findings suggest that exosomes exert anti-inflammatory effects by targeting the ROCK1/PTEN pathway and exhibit pro-angiogenic effects via delivery of miR-132 and miR-146a. Taken together, these results suggest that exosomes may be promising therapeutic candidates for curing diseases involved in inflammation and angiogenesis.ope
Survey Analysis of ABO Antibody Titration at Four University Hospitals in Korea.
BACKGROUND: The ABO antibody titration is important, especially in case of ABO-incompatible hemolytic disease of newborn, ABO-incompatible bone marrow or solid organ transplantation. However, no standard method for ABO antibody titration has yet been established. We surveyed four university hospitals about the methods of ABO antibody titration and performed inter-laboratory proficiency tests. METHODS: Detailed methods of ABO antibody titration were surveyed at four university hospitals. ABO antibody titer was measured by their customary methods using serum samples from six healthy volunteers with blood groups A (n=2), B (n=2) and O (n=2). RESULTS: Procedures of ABO antibody titration, reportable ranges, sample diluent, source of reagent RBCs and interpretation of end-point were different among four university hospitals. Inter-institutional maximum differences of IgM and IgG ABO antibody titer were 16-fold and 32-fold, respectively. CONCLUSION: Standardization of ABO antibody titration method is needed to reduce inter-laboratory variability, and a periodical external quality control survey is necessary to improve the accuracy of the titrationope
Performance review of the National Blood Safety Improvement Project in Korea (2004-2009)
BACKGROUND:
In 2004, the Korean government and blood transfusion community deliberated on the issue of a national blood system reform and agreed to implement a 5-year project (2004-2009) to further improve safety measures. Our study delineates the basis of the current national blood program and analyzes the performance of this 5-year project initiated by the Korean government.
METHODS:
A performance review of the 5-year project was conducted from May 2009 to February 2010 using various approaches. Numerous data and documentation were collected from the Korean Red Cross and the Korean Centers for Disease Control and Prevention and reviewed by experts. Approximately 20 interviews with representatives of stakeholder groups were conducted to gather information, opinions, and perceptions. We conducted a nationwide field survey on a total of 144 blood donor centers.
RESULTS:
Among the 5 major categories of the 5-year project, blood donor recruitment, laboratory testing, and product manufacturing were improved in terms of quality performance. Specifically, government's financial support ensured that the infrastructure of blood donor centers and blood laboratory centers improved. The pivotal role of the government contributed to improvements in the national blood program and enhanced national surveillance for blood safety.
CONCLUSION:
Korea has made a tremendous effort with positive outcomes to provide safety measures for blood products for transfusion in its citizens. In all areas of blood management, from blood donations to transfusions, continuous developments in monitoring safety standards and practices are paramount.ope
A Case of Washed Platelet Transfusion in a Patient with History of Recurrent Transfusion Reaction Ji Yeon Sohn1, Joo-Hyoung Hwang1, Hyang-lae Lee1
Anaphylactic transfusion reaction is caused by deficiency of certain protein(s) in the recipient. We report on the experience of platelet count recovery using washed platelets for transfusion in a patient who developed an anaphylactic transfusion reaction. A 50-year old male diagnosed with angioimmunoblastic T-cell lymphoma was treated with chemotherapy followed by autologous hematopoietic stem cell transplantation. Immediately after starting transfusion of apheresis platelets, he began sweating and complained of visual impairment, chest discomfort, and abdominal pain. Both systolic and diastolic blood pressures and oxygen saturation monitored by pulse oximetry were decreased. Platelet transfusion was discontinued immediately and hydrocortisone was administered, and the symptoms and signs were resolved within two hours. Laboratory test using post-transfusion blood showed no apparent evidence of hemolysis. Platelet washing procedure using normal saline three times was newly set to prevent anaphylactic reaction in the patient. Transfusions of washed platelets were performed 20 times for 60 days, and the patient showed no anaphylactic reaction during this period. He showed no evidence of immunoglobulin A, haptoglobin, C3, or C4 deficiencies. We confirmed that washed platelet transfusion is highly effective for prevention of anaphylactic transfusion reaction.ope
- β¦